Instytut Psychiatrii I Neurologii — Clinical Trial Site

24 Registered trials

11 Currently recruiting

Organisation

Instytut Psychiatrii I Neurologii

Location

Warsaw, Poland

Identifier

ORG-100028715

Address

Ul. Jana III Sobieskiego 9, 02-957, Poland

Departments

#5817:II Klinika Neurologiczna
2nd Department of Neurology
Department of Clinical Neurophysiology
Department of Neurology
II Klinika Neurologiczna
II Klinika Psychiatryczna
III Klinika Psychiatryczna
Klinika II Neurologii
KLINIKA NERWIC, ZABURZEŃ OSOBOWOŚCI I ODŻYWIANIA
Osrodek Medycyny Snu Instytutu Psychiatrii i Neurologii
Psychiatry
Universyty Medical center
Zakład Farmakologii
Zakład Farmakologii i Fizjologii Układu Nerwowego
Zakład Farmakologii i Fizjologii Układu Nerwowego

Clinical trials at this site (24)

Search interface

Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) Pending

2024-516805-22-00 Major Depressive Disorder 5
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) - X-CE… Recruiting

2025-522775-29-00 Depressive episodes associated with Bipolar disorder I 5 2026-06-05
A Phase 3 Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Bipol… Recruiting

2025-521845-26-00 BP-I mania or mania with mixed features 5 2026-03-02
A Phase 3 Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Recruiting

2024-520259-26-00 Mania or Mania with Mixed Features in Bipolar-I Disorde 5 2025-09-25
A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with NMDAR or LGI1 mediated autoimm… Recruiting

2023-504226-18-00 NMDAR or LGI1 mediated autoimmune Encephalitis 5 2022-11-30
Identification of mitochondrial biomarkers reflecting omaveloxolone treatment (in FA patients) Recruiting

2025-523881-26-00 Friedreich's ataxia 6 2026-05-27
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Recruiting

2024-520165-32-00 BP-I mania or mania with mixed features 5 2025-11-04
A Phase 3 Trial to Assess CYB003 in Major Depressive Disorder Recruiting

2024-519270-40-00 Major Depressive Disorder 5 2025-10-30
A study to determine if BHV-7000 is safe in adults with refractory focal onset epilepsy Recruiting

2023-508813-18-00 Refractory Focal Onset Epilepsy 4 2024-12-18
Randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of dimethyl fumarate in brain atrophy reduction, synaptic … Recruiting

2024-517214-16-00 Alzheimer’s disease 4 2024-10-28
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Recruiting

2023-508539-30-00 Refractory Focal Onset Epilepsy 4 2024-10-10
Study to evaluate the efficacy and safety of low-dose aspirin as an add-on to standard therapy in patients with bipolar disorder (ASPIRIN BD… Recruiting

2024-516584-86-00 Bipolar Affective Disorder 4 2023-05-19
Cladribine for the treatment of secondary progressive MS - randomized, double-blind, placebo-controlled study. Ended

2024-516992-33-02 Multiple sclerosis secondary progressive form 4 2025-01-30
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis Ended

2022-502609-14-00 Relapsing multiple sclerosis (RMS) 5 2020-12-09
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sc… Ended

2023-506515-18-00 Primary Progressive Multiple Sclerosis (PPMS) 5 2020-10-23
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Relapsing Multiple Sclerosis Ended

2023-506467-34-00 Relapsing Multiple Sclerosis (MS) 5 2020-10-20
Study to compare the efficacy and safety of NT 201 (botulinum toxin) with placebo for the treatment of lower limb spasticity caused by strok… Ended

2023-505810-12-00 Lower limb spasticity 5 2019-09-03
An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS Ended

2023-507906-15-00 Relapsing multiple sclerosis (RMS) 5 2019-01-30
A study to learn about how elinzanetant works and how safe it is in women having sleep disturbances associated with menopause Ended

2023-504955-28-01 Sleep disturbances associated with menopause 4 2024-03-14
Study to Evaluate the Efficacy and Safety of Intranasal BPL-003 in Patients with Treatment Resistant Depression Ended

2024-513457-70-00 Treatment-Resistant Depression (TRD) 4 2023-09-08
A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran… Ended

2023-503793-20-00 Prevention of ischemic stroke in patients post acute no 5 2023-01-18
A study to test long-term safety of Iclepertin in people with schizophrenia who took part in a previous CONNEX study Ended

2024-511560-93-00 Schizophrenia 5 2022-03-29
Prospective Study to Characterize the Pharmacokinetics and Pharmacodynamics of Cufence (Trientine Dihydrochloride) in Wilson Disease Patient… Ended

2024-516431-27-00 Wilson’s Disease 6 2021-02-23
A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-la … Ended

2023-506543-41-00 Multiple sclerosis (MS) 5 2018-07-25